Jiangsu Vicaire Completes Series C Financing of Over RMB 450 Million to Advance Innovative Drug Pipeline and CRO/CDMO Business
Jiangsu Vcare
Chemical Innovative Drug Developer
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (“Jiangsu Vcare”) completed a Series C financing round exceeding RMB 450 million, with joint investment from China Life Equity Investment, Deyi Capital, Hongyao Sci-Tech Innovation, existing shareholder Nanjing Innovation Investment Group, Hangzhou Huadian Investment, and other institutions. The participation of new investors and the continued support from existing shareholders demonstrate the market’s strong confidence and high expectations in Jiangsu Vcare. The funds raised in this round will be primarily used to accelerate the advancement of its innovative drug R&D pipeline and to sustain the development of its full-industry-chain CRO/CDMO services.
Jiangsu Vcare Completes Series C Financing Amidst a Challenging Market Environment, Demonstrating Strong Growth Potential and Core Competitiveness. Since its inception, Jiangsu Vcare has established a strategic layout featuring the synergistic development of two core businesses: independent R&D of innovative drugs and full-industry-chain CRO/CDMO services. The company has consistently prioritized independent innovation and customer service as the focal points of its growth. Currently, both core businesses are experiencing rapid development, with multiple innovative drug candidates in clinical trials reaching critical stages, while the CRO/CDMO services business continues to achieve sustained growth, thereby building a robust “moat” in terms of products, technology, and services. Jiangsu Vcare is confident that, with strong support from its investors, it will successfully drive the company toward high-quality development.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated
We have always believed that fundraising is not merely about “raising capital,” but rather about forging a “community of shared destiny” with partners who share our values, trust, commitment, and professionalism, to jointly achieve significant business success. In the current “winter” of the pharmaceutical industry, successfully completing this round of financing is no small feat, fully demonstrating the high recognition and expectations of the capital market for the Vcare PharmaTech team. Standing at a new stage of development, we will continue to firmly focus on our two core businesses, leverage differentiated strategies, seize policy and market opportunities, and steadfastly advance in innovative drug R&D and drug development services, ensuring steady and long-term progress. While accelerating our own high-quality development, we are committed to contributing to the robust growth of the pharmaceutical industry.
China Life Equity stated
Jiangsu Vcare PharmaTech has a distinctive pipeline of innovative drugs and is deeply entrenched in the CRO/CDMO market across the entire pharmaceutical industry chain. We look forward to our collaboration accelerating the launch of Jiangsu Vcare’s innovative drugs, expanding production capacity at its service-oriented manufacturing bases, and helping it build a first-class, internationally renowned R&D and manufacturing service platform covering the full industry chain and lifecycle of chemical drugs.
Deyi Capital stated
Jiangsu Vcare’s management team boasts extensive experience in the pharmaceutical industry and demonstrates strong execution capabilities. Its innovative drug pipeline is strategically focused on the cardiovascular and cerebrovascular fields, holding promise for further addressing substantial unmet clinical needs. The small-molecule CRO/CDMO business is experiencing steady growth, providing sustained momentum for Jiangsu Vcare’s development. We anticipate that Jiangsu Vcare will become a leading domestic and internationally renowned biopharmaceutical group in the near future.
About China Life Equity
Upholding the philosophy of investing in the future, innovation, and value, China Life Equity Investment fully leverages the professional advantages of insurance capital and China Life’s sense of responsibility to serve national strategies, support the real economy, and demonstrate China Life’s commitment. With a focus on technological self-reliance and strength, China Life Equity Investment concentrates on core technologies and has invested in multiple innovative high-tech enterprises that break foreign monopolies on technology and products and are dedicated to resolving critical “chokepoint” challenges. The portfolio companies are distributed across key fields and pivotal links in the healthcare and technological innovation industries, empowering a cohort of leading enterprises with significant voice and influence in industrial development, and striving to enhance the security and competitiveness of industrial and supply chains.
About Deyi Capital
Deyi Capital prioritizes investments in sectors such as healthcare and next-generation information technology. Its management team boasts extensive experience in investment, investment banking, and industry operations, along with broad market resources and specialized post-investment service and management capabilities. In the biopharmaceutical sector, Deyi Capital has invested in numerous companies, including Zeltis Pharma (688266.SH), Allist Pharmaceuticals (688578.SH), Yifang Biopharma (688382.SH), Yuanli Life Sciences, Kewang Medicine, GenFleet Therapeutics, Aikera Biopharma, Weilizhibo, Yingli Pharma, Zhimeng Medicine, Yinuo Medicine, and BridGene.
About Jiangsu Vcare
Jiangsu Vcare PharmaTech Co., Ltd., established in 2010, is a high-tech pharmaceutical enterprise dedicated to the development of innovative drugs and cutting-edge therapies. The company currently employs over 700 staff members, including 16 PhD holders and nearly 200 master’s degree holders, with technical personnel accounting for more than 84% of its workforce. Located in the Nanjing Jiangbei New Area Bio-medicine Valley, a national-level new area, the company has invested RMB 200 million in constructing a state-of-the-art drug R&D center on a 20-mu site with a building area of 21,000 square meters. Its wholly-owned subsidiary, Nanjing Vcare Biopharmaceutical Technology Co., Ltd., specializes in providing CRO/CDMO services across the entire pharmaceutical industry chain.
The company currently has five Phase I innovative drug candidates in clinical development: Vicagrel capsules, VC004 capsules (key Phase II clinical trial initiated), VC004 gel (clinical trial approved), VC005 tablets (Phase II clinical trial initiated), and VC005 gel (Phase I clinical trial initiated). Additionally, there are multiple preclinical research projects covering various disease areas such as cardiovascular and cerebrovascular diseases, oncology, and autoimmune disorders, forming a tiered pipeline development structure.
Guided by R&D and oriented toward industrialization, the Company has established a high-end drug R&D system and technology platform that combines innovation with competitiveness. It has successively established a Jiangsu Provincial Enterprise Academician Workstation and a Nanjing Postdoctoral Innovation Practice Base, co-established an Enterprise Graduate Student Workstation with China Pharmaceutical University, and been included in the Nanjing Unicorn Cultivation Enterprises list, the Jiangsu Province Specialized, Refined, Differential, and Innovative SMEs list, the Jiangsu Province Chemical Innovative Drug Engineering Technology Research Center, and the Nanjing Innovative Leading Enterprise Cultivation Pool. Its wholly-owned subsidiary, Nanjing Vcare, has ranked among the Top 20 Chinese Pharmaceutical CRO Companies for consecutive years. From 2021 to 2022, the Company completed two rounds of financing, raising a total of over RMB 500 million. Looking ahead, leveraging more than a decade of experience in innovative drug R&D, the Company aims to develop multiple Class I innovative drug products designed to address unmet clinical needs through differentiated solutions.